NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019
William G. Wierda(The University of Texas MD Anderson Cancer Center), Hema Sundar(National Comprehensive Cancer Network), Jeremy S. Abramson(Massachusetts General Hospital), Tanya Siddiqi(City Of Hope National Medical Center), Brian T. Hill(Cleveland Clinic), Claudio A. Mosse(Breast Cancer Research Foundation), Asher Chanan‐Khan(WinnMed), Randall S. Davis(University of Colorado Cancer Center), Steven Coutré(Georgetown University), Jennifer R. Brown(Dana-Farber Cancer Institute), Vishala T. Neppalli(UC San Diego Health System), Deborah M. Stephens(University of North Carolina at Chapel Hill), Thomas J. Kipps(University of California San Diego), Danielle M. Brander(Duke University), Christopher D.�M. Fletcher(Brigham and Women's Hospital), Mazyar Shadman(University of Washington), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), Brad S. Kahl(UW Health University Hospital), Nadia Khan(Fox Chase Cancer Center), Shuo Ma(Nantong University), Julio C. Chávez(Moffitt Cancer Center), Nina Wagner(Sidney Kimmel Comprehensive Cancer Center), Anthony Mato(Memorial Sloan Kettering Cancer Center), Greg Bociek(Susan Thompson Buffett Foundation), Mary A. Dwyer(National Comprehensive Cancer Network), Sami N. Malek(University of Michigan), Manali Kamdar(University of Colorado Cancer Center), S Bilgrami(Yale Cancer Center), John C. Byrd(University of Cincinnati)
Cited by 94
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k